Table 4.
Crude incidences of recurrent nonfatal or fatal VTE in patients without a prior history of VTE
| Risk factor profile | EINSTEIN EXTENSION | EINSTEIN CHOICE | EINSTEIN CHOICE | EINSTEIN EXTENSION and EINSTEIN CHOICE | EINSTEIN EXTENSION | EINSTEIN CHOICE |
|---|---|---|---|---|---|---|
| Rivaroxaban 20 mg (N = 488) | Rivaroxaban 20 mg (N = 909) | Rivaroxaban 10 mg (N = 930) | All rivaroxaban (N = 2327) | Placebo (N = 502) | Aspirin (N = 937) | |
| Unprovoked, n/N (%) | 4/198 (2.0) | 5/363 (1.4) | 5/407 (1.2) | 14/968 (1.5) | 18/203 (8.9) | 16/392 (4.1) |
| Provoked by major persistent risk factors, n/N (%) | 0/17 (0.0) | 0/30 (0.0) | 0/21 (0.0) | 0/68 (0.0) | 1/26 (3.9) | 1/29 (3.5) |
| Provoked by minor persistent risk factors, n/N (%) | 3/201 (1.5) | 8/383 (2.1) | 6/367 (1.6) | 17/951 (1.8) | 15/206 (7.3) | 12/382 (3.1) |
| Provoked by minor transient risk factors, n/N (%) | 0/56 (0.0) | 1/84 (1.2) | 0/86 (0.0) | 1/226 (0.4) | 4/52 (7.7) | 4/106 (3.8) |
| Provoked by major transient risk factors, n/N (%) | 0/16 (0.0) | 0/49 (0.0) | 0/49 (0.0) | 0/114 (0.0) | 0/15 (0.0) | 0/28 (0.0) |